Intent Biologics

Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.

Proprietary platform for producing a Purified Exosome Product (PEP Biologic™), leveraging exosomes as natural signaling vesicles to promote tissue regeneration and modulate immune responses. Based on Mayo Clinic research and RION's biomanufacturing techniques.

In chronic wounds, competitors include advanced wound care dressings, recombinant growth factors (e.g., Regranex), and cell-based therapies. In autoimmune dermatology, the landscape is crowded with systemic biologics (e.g., Dupixent) and JAK inhibitors, though few are topical biologics. Intent's main differentiation is its novel mechanism of action using purified exosomes as a multimodal regenerative and immunomodulatory signal.